TMEM256-PLSCR3: A Drug Target / Disease Biomarker (G100529211)

Target Name: TMEM256-PLSCR3

NCBI ID: G100529211

TMEM256-PLSCR3

Other Name(s): TMEM256-PLSCR3 readthrough (NMD candidate) | PLSCR3 | C17orf61-PLSCR3

TMEM256-PLSCR3: A Drug Target / Disease Biomarker

TMEM256-PLSCR3 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell MHC class I region, which is a protein that is involved in the presentation of antigens to T-cells. TMEM256-PLSCR3 has been shown to play a role in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it is of great interest to researchers as a potential drug target or biomarker.

One of the key functions of TMEM256-PLSCR3 is its role in the immune system. It is a major contributor to the presentation of antigens to T-cells, which are responsible for cell-mediated immunity. T-cells are a critical component of the immune system, as they are responsible for detecting and responding to the presence of foreign substances in the body. TMEM256-PLSCR3 plays a role in helping T-cells recognize and respond to these foreign substances.

In addition to its role in the immune system, TMEM256-PLSCR3 is also involved in the development and progression of a variety of diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of progressive neurological symptoms. TMEM256-PLSCR3 may be a potential drug target or biomarker for these conditions, as it has been shown to play a role in the development and progression of these diseases.

Another potential function of TMEM256-PLSCR3 is its role in cancer. Cancer is a condition in which cells in the body begin to divide out of control, leading to the formation of tumors. TMEM256-PLSCR3 has been shown to be involved in the development and progression of cancer, as it has been shown to contribute to the immune evasion that cancer cells use to evade the immune system. As a result, TMEM256-PLSCR3 may be a potential drug target or biomarker for cancer.

In conclusion, TMEM256-PLSCR3 is a protein that is expressed in various tissues of the body and is involved in a variety of functions, including the immune system and the development and progression of diseases. As a result, it is of great interest to researchers as a potential drug target or biomarker. Further research is needed to fully understand the role of TMEM256-PLSCR3 in these processes and to determine its potential as a drug or biomarker.

Protein Name: TMEM256-PLSCR3 Readthrough (NMD Candidate)

The "TMEM256-PLSCR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM256-PLSCR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets